CS Paper Radar

VITAL: A Framework for Validating Agentic AI in Pharmaceutical Drug Development and Clinical Trial Operations

Sandeep Burugupalli, Pedro Matos-Filipe, Andrea Hita Ardiaca, Adam Taylor, Alex Grigorenko, Natalia Jakubiak, Xin Yu, Raghav Mani, Sherry Mangla, Alvi Lai, Rachel C. Mercado, Pratik Shah, Raja Shankar

cs.AI ·submitted 2026-11-17 15:55 UTC · v1

Abstract

Current assurance approaches do not establish whether evidence is sufficient to validate, monitor and govern agentic artificial intelligence (AI) within a pharmaceutical context of use. Plausible outputs may conceal failures in retrieval, reasoning, orchestration or human-control points, where reference standards are unavailable. We developed and operationalised VITAL (Validation by Intended use, Traceability, Autonomy and Lifecycle evidence), a validation framework for agents in clinical development, through landscape analysis, regulatory and standards mapping, expert interviews and multi-stakeholder refinement. VITAL integrates context of use, controls, behavioural validation and lifecycle evidence within a risk-adjusted framework. We applied VITAL across epidemiology and treatment-landscape analysis, site selection, enrolment rescue and trial-design trade-off support to translate autonomy, reversibility, transparency and patient impact into proportionate validation activities, evidence requirements and auditable reconstruction of system behaviour. VITAL may inform evidence requirements and lifecycle accountability for higher-risk pharmaceutical uses; evaluation should assess reproducibility across assessors, organisations and system configurations.

Closest papers

Nearest neighbours by meaning across the whole index.

TrialAtlas: Multi-Agent Research Organization for Clinical Trial Design and Optimization

cs.CL ·2026-09-18 ·Jiacheng Lin, Zifeng Wang, Zheng Chen, Erick Scott, Ziwei Yang +3 more
similarity 0.69
Abstract

Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely on clinical development planning (CDP) and probability of technical and regulatory success assessment to anticipate development risks, yet these decisions remain labor-intensive and subjective, requiring experts across clinical science, statistics, regulatory affairs, and competitive intelligence to jointly acquire, synthesize, and reason over heterogeneous evidence. Here, we introduce TrialAtlas, a memory-augmented multi-agent research organization for CDP that mirrors this collaborative process by coordinating specialized agents for literature synthesis, competitive trial intelligence, regulatory precedent analysis, and integrated reasoning over trial design and development risk. TrialAtlas further learns from historical clinical trials and regulatory outcomes, including prior New Drug Applications (NDAs), to ground its decisions in accumulated development experience. To evaluate these capabilities in an authentic regulatory setting, we introduce TrialAtlasBench, constructed from 291 FDA Complete Response Letters and spanning three practical tasks: detecting trial design deficiencies, recommending actionable design improvements, and predicting technical and regulatory success. TrialAtlas achieves an F1 score of 50.0% for deficiency detection, outperforming the strongest baseline by 6.1 points, and reaches 85.3% balanced accuracy and 84.7% F1 for prediction of technical and regulatory success, improving over the best baselines by 6.7 points in balanced accuracy and 12.0 points in Cohen's kappa. In expert evaluation, 86.4% of TrialAtlas-generated concerns were judged valid, compared with 83.1% for OpenAI DeepResearch and 59.3% for Gemini DeepResearch.

0.40

AI Morbidity and Mortality: A Framework for Clinical AI Failure Review

cs.AI cs.HC ·2026-08-31 ·Paulius Mui, Dean F. Sittig, Steve Labkoff, Sanjay Basu
similarity 0.69
Abstract

Clinical artificial intelligence is increasingly embedded in real-world care, yet existing safety mechanisms are poorly suited to reconstructing and learning from individual AI-related errors and near-misses. Aggregate model monitoring can identify performance changes, and traditional patient safety reporting can capture adverse events, but neither is designed to explain how risk emerges across the interaction among AI systems, clinicians, workflows, and institutional controls. We propose AI Morbidity and Mortality (AI M&M), a structured, blameless framework for case-based review of clinical AI failures. The framework combines standardized case intake, evidence preservation and investigator-level reconstruction, tool-in-loop attribution, and corrective-action tracking. Each event is classified across four linked dimensions: Trigger - Mechanism - Clinical Pathway - Corrective Action, separating the condition that exposed a vulnerability from the process that produced risk, its consequence for care, and the remediation assigned. We demonstrate the framework using five illustrative outpatient medication and clinical decision-support cases; two clinician reviewers independently applied all four classification axes and reached agreement across all 20 axis-level classifications. AI M&M is intended to complement, rather than replace, model monitoring, patient safety reporting, and regulatory oversight by converting individual AI-in-workflow failures into actionable institutional learning. Prospective evaluation across institutions, AI systems, and clinical settings is needed.

0.13

PRISMATIC : Prescription Risk Inspection System for Multi-Agent Treatment Interaction in Clinical Decision-Making

cs.CL cs.AI ·2026-10-14 ·Ziyang Ling, Shuyu Lu, Ziyi Chen
hot direction similarity 0.66
Abstract

Medical prescribing errors for multimorbid patients, who require complex drug regimens, are a major patient safety concern. These errors often stem from fragmented decision-making across medical specialties, a critical coordination failure that leads to adverse drug events and rehospitalizations. To address this coordination challenge, we introduce PRISMATIC, a multi-agent architecture where specialized agents, each representing a workflow role, collaboratively generate and refine treatment plans. Operating on a blackboard architecture, the system first structures patient information from clinical notes, then iteratively develops safe, rational, and interpretable drug regimens. The agents' collaboration is governed by two novel adaptive coordination mechanisms: (1) Dynamic Self-Updating Weight Adjustment (DSWA), a long-term mechanism that adjusts the influence weights of agents based on historical case outcomes, enabling the system to adapt and trust more reliable specialists over time. (2) Discrepancy Feedback Precise Calibration (DFPC), a short-term mechanism where agents provide iterative feedback to resolve disagreements and eliminate prescription conflicts for the current patient. Experiments on patient records from the MIMIC-IV database show that PRISMATIC significantly reduces drug conflicts, improves prescription coverage, and enhances treatment consistency compared to strong LLM baselines. Our work demonstrates that structuring clinical co-treatment as a multi-agent coordination problem offers a promising path toward safer and more coherent multidisease management.

0.29

Making Sense of Animal-to-Human Drug Development Evidence: Stakeholder Practices, Challenges, and Requirements for AI Tools

cs.HC ·2026-09-30 ·Rosni Vasu, Simona E. Doneva, Benjamin V. Ineichen
similarity 0.65
Abstract · 24 pages, 5 Figures, 12 main pages

Animal models are widely used to study human biology and health interventions, yet translating findings from animal studies to humans remains challenging. Evidence across preclinical and clinical research informs experimental and translational decisions. Artificial Intelligence (AI) tools are increasingly reshaping how this evidence is searched, synthesized, and used, but it remains unclear how they should support the diverse stakeholders involved in assessing animal-to-human evidence. We conducted semi-structured interviews with 13 stakeholders to examine their evidence practices, challenges, and expectations for AI support. We found that stakeholders approach the same incomplete evidence base with different goals, expertise, and heuristics. Participants valued AI particularly for locating, screening, and extracting evidence, but were more cautious about automated interpretation and quality judgments. They emphasized transparency, source traceability, uncertainty communication, and human oversight. Based on these findings, we derive design implications for role-sensitive AI tools that support more systematic and transparent reasoning about animal-to-human translation.

0.18

"It's still 100% on me": Designing AI Tools for the Intersection of Physicians' Care and Legal Infrastructures

cs.HC ·2026-11-11 ·Gennie Mansi, Julia Kim, Lynn Dombrowski, Mark Riedl, Naveena Karusala
similarity 0.64
Abstract · 27 pages, 0 figures

Laws and regulations deeply shape physicians' workflows and impact how they incorporate AI-based decision support tools to care for patients. Despite calls to comply with legal standards, many AI-based decision support tools have not transitioned well to clinical settings. The medical community remains concerned about their legal liability, risks to patients, and limited clinical value of such tools. To better understand how to address these concerns in the design of AI tools for clinical decision-making, we conducted 19 interviews with physicians in the U.S. We used scenario-based design to investigate physicians' legal concerns in the context of an AI-based drug recommendation tool. Drawing on the ethics of care, we surface connections between physicians' care and the healthcare laws and regulations that deeply shape their information needs. We describe how physicians wanted to use the tool in individual and collective practices to care for themselves, their patients, their colleagues, work institution, and even the broader medical profession. We discuss how the design of AI-based decision support tools can present legal ambiguities that would prevent their caring actions and lead to non-use of the AI tool. Through our work, we contribute to responsible AI development in healthcare. Our analysis illuminates why and how certain kinds of information reduce legal ambiguity and support physicians' care when using AI-based decision support tools. We contribute an understanding of how to help physicians navigate legal liability and draw implications for grounding AI tools' designs in their care.

0.38

Research with AI Agents: How Agentic Systems Are Changing Scientific Work

cs.CY ·2026-09-25 ·Johannes Lotz, Markus Wenzel
similarity 0.64
Abstract · 6 pages, 1 figure. English translation followed by the original German version. Submitted to Die Pathologie (Springer Medizin)

Background. Agentic AI systems independently decompose tasks such as literature search, data analysis, and programming into subtasks, search the web, access databases, and execute code. This allows them to perform digital research tasks at high speed. Objectives. Under what conditions does the use of agentic systems produce reliable efficiency gains, and which tasks remain with researchers? Materials and methods. Summary of current studies on literature searches, data analysis, software development, and clinical decision support. Results. For digital activities, work shifts from execution to steering and review. Efficiency gains are greatest when expected behavior can be formalized in advance and tested automatically. In complex agentic systems, recorded sequences of reasoning steps and tool calls can quickly become too extensive for human review. Furthermore, explanations generated by the model do not reliably reflect how an output was produced. One possible step toward more reliable systems is the validation of individual components. The limited reviewability extends beyond research itself; the review of scientific articles and grant proposals is also reaching capacity limits. In pathology, curated and annotated data, researchers' own analytical skills, and institutional exchange of experience are becoming increasingly important. Conclusions. Researchers remain responsible for their results. They must determine what to delegate and how to review the results. The importance of a research question to patients, the field, and society cannot be fully assessed using formalized criteria and remains a matter of expert judgment. Agentic systems can free up time for this.

0.09

Designing a Robust LLM-Based Evaluation System for Agentic AI in Drug Discovery Through Human Alignment

cs.LG ·2026-08-21 ·Emma Granqvist, Rocío Mercado, Samuel Genheden
similarity 0.63
Abstract

Agentic large language model (LLM) systems are reshaping scientific workflows in chemistry and drug discovery, but evaluating their open-ended, tool-augmented outputs remains a fundamental bottleneck. The LLM-as-a-Judge paradigm has emerged as a scalable alternative, but existing drug discovery benchmarks deploy LLM judges without validating their alignment with human experts. In this work, we present an LLM-as-a-Judge evaluation framework for ChatInvent, an agentic drug discovery assistant deployed at AstraZeneca, with five contributions. First, we define four output-quality evaluation dimensions---Completeness, Relevancy, Structural Clarity, and Scope Adherence---alongside deterministic Tool Call Correctness checks. Second, we validate the judge through a human alignment study with five expert annotators, comparing Gemini 3.1 Pro, Claude Opus 4.7, GPT-5, and Llama 3.1 70B as candidate judges. Third, we optimize the best-performing judge using few-shot demonstrations of human-annotated examples, improving alignment with the human majority vote from 0.80 to 0.86. Fourth, applying the optimized judge to 70 held-out questions, we surface concrete limitations and find no strong evidence that informal phrasing degrades output quality; it may, however, still be helpful to have the LLM rewrite the original question before querying the agent. Finally, we extend the framework to 38 adversarial questions that are ambiguous, invalid, out-of-scope or ethically sensitive, and show that the agent's refusal behavior is guided by the stated intent of a request. Our framework provides a reusable template for human-aligned evaluation of agentic systems in scientific domains.

0.24

Coupled Graph--Policy Distillation for Personalized Medication Safety in Older Adults with Multimorbidity

cs.AI ·2026-08-10 ·Zihan Wang, Anglin Liu, Rongyi Wang, Dantong Li, Yi Lu +4 more
benchmark similarity 0.63
Abstract

Large language model (LLM) agents can support medication review between clinical visits, but safe choices for older adults with multimorbidity depend on conditions, medications, and geriatric risks that users may omit. We introduce ATLAS, a coupled graph--policy distillation framework for patient-adaptive medication safety. ATLAS structures guideline evidence as a medication-safety graph. Targeted questions update the patient state and distill relevant relations into a patient-specific medication conflict graph (PMCG). A risk-first multi-agent policy uses the PMCG to screen contraindications, assess cautions and monitoring needs, identify safer alternatives, and verify the final medication plan. We also introduce GeriMedBench, an interactive benchmark that tests safety-critical information acquisition and evidence-based decision revision. Across a European non-interactive multimorbidity benchmark, an Asian interactive multimorbidity benchmark, and an Asian non-interactive cross-guideline benchmark, ATLAS achieves the strongest complete-decision performance among the compared systems. On the European non-interactive multimorbidity benchmark, it exceeds the strongest proprietary LLM baseline by 53.73 points in Strict Success Rate and 14.63 points in overall safety reasoning score (OSRS), with no unsafe recommendations under the automated evaluator. A blinded clinician evaluation gives ATLAS higher mean ratings across all five criteria and flags potentially unsafe recommendations in one ATLAS case and two Gemini cases.

0.04